Market Overview:
Statins are expected to dominate this market owing to their high efficacy and widespread use for treating dyslipidemias. On the basis of application, this market is segmented into online pharmacy, retail pharmacy, hospital pharmacy,, and others. The online pharmacy segment is projected to grow at a higher CAGR during the forecast period as patients are increasingly shifting towards purchasing drugs online due to convenience and lower prices offered by e-commerce platforms. Geographically speaking,, North America dominates this market followed by Europe; however,.
Product Definition:
Triglycerides are a type of fat that is present in the blood and that is used by the body for energy. When there are high levels of triglycerides in the blood, this can increase the risk for developing heart disease and other health problems.
Statins:
Statin drugs are the most commonly used medications for lowering bad cholesterol and triglyceride levels. They work by blocking some of the enzymes that build up to harmful lipid levels in the blood. Statins are also used as anti-inflammatory agents, which helps in reducing pain due to inflammation caused due to rheumatoid arthritis or osteoarthritis.
Fibrates:
Fibrates are organic compounds that help in the breakdown of fats into free fatty acids and glycerol. They are used as anti-obesity agents for preventing or reducing fat accumulation in the body. Fibrates act by increasing the activity of a particular type of enzyme named fibroblast growth factor receptor (FGFR) which is involved in fat metabolism.
Application Insights:
Online pharmacy held the largest market share of more than 40.0% in 2017 owing to the availability of a wide range of products at lower prices with efficient customer support. Moreover, there is an increasing number of online pharmacies due to easy access and payment options for customers who are not able to go to a pharmacy due to work or other commitments.
This factor has led retailers¢â‚¬â„¢ confidence that they can provide high-quality medicines at affordable prices which will drive their demand over the next few years.
Hospital pharmacies are expected witness moderate growth as these facilities have larger volumes and wider product offerings compared with their counterparts operating outside hospitals premises (extraction).
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position during the forecast period owing to high healthcare expenditure, technological advancements, and increasing prevalence of CVDs & diabetes.S.
Asia Pacific is anticipated to witness lucrative growth over the forecast period due to rising disposable income coupled with growing population especially in India & China resulting into increased demand for various pharmaceutical products including HMG-CoA reductase inhibitors (statins) and fibrates that lower triglycerides levels leading into a profitable future for all stakeholders involved including manufacturers, distributors, suppliers as well as end users.
Growth Factors:
- Increasing prevalence of hypertriglyceridemia: The global prevalence of hypertriglyceridemia is estimated to be around 25%. This number is expected to grow in the coming years due to the increasing incidence of obesity and diabetes.
- Growing awareness about the health risks associated with high triglyceride levels: There is a growing awareness among people about the health risks associated with high triglyceride levels. This is driving them to seek treatment for hypertriglyceridemia.
- Availability of novel therapies: The availability of novel therapies such as monoclonal antibodies and small molecules is helping to drive growth in the hypertriglyceridemia therapeutic market. These new therapies are providing physicians with more options for treating patients with this condition.
- Rising demand for preventive treatments: There is a rising demand for preventive treatments for conditions such as hypertriglyceridemia, which can help reduce the risk of developing serious health problems later in life. This is driving growth in the market for Hypertriglyceridemiatherapeutics . 5
Scope Of The Report
Report Attributes
Report Details
Report Title
Hypertriglyceridemia Therapeutic Market Research Report
By Type
Statins, Fibrates, Niacin, Omega-3 Fatty Acids, Others
By Application
Online Pharmacy, Retail Pharmacy, Hospital Pharmacy, Others
By Companies
Sanofi, GlaxoSmithKline, Biocon, Novo Nordisk, Tonghua Dongbao Pharmaceutical, Oramed Pharmaceuticals, Merck, Julphar, Eli Lilly and Company, Bristol-Myers Squibb Company, Pfizer, AbbVie
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
151
Number of Tables & Figures
106
Customization Available
Yes, the report can be customized as per your need.
Global Hypertriglyceridemia Therapeutic Market Report Segments:
The global Hypertriglyceridemia Therapeutic market is segmented on the basis of:
Types
Statins, Fibrates, Niacin, Omega-3 Fatty Acids, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Online Pharmacy, Retail Pharmacy, Hospital Pharmacy, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Sanofi
- GlaxoSmithKline
- Biocon
- Novo Nordisk
- Tonghua Dongbao Pharmaceutical
- Oramed Pharmaceuticals
- Merck
- Julphar
- Eli Lilly and Company
- Bristol-Myers Squibb Company
- Pfizer
- AbbVie
Highlights of The Hypertriglyceridemia Therapeutic Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Statins
- Fibrates
- Niacin
- Omega-3 Fatty Acids
- Others
- By Application:
- Online Pharmacy
- Retail Pharmacy
- Hospital Pharmacy
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Hypertriglyceridemia Therapeutic Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Hypertriglyceridemia is a condition in which there is too much triglyceride (a type of fat) in the blood. Hypertriglyceridemia can be caused by many things, including obesity, genetics, and certain medications. Treatment for hypertriglyceridemia depends on the cause and may include lifestyle changes, medication therapy, or surgery.
Some of the major players in the hypertriglyceridemia therapeutic market are Sanofi, GlaxoSmithKline, Biocon, Novo Nordisk, Tonghua Dongbao Pharmaceutical, Oramed Pharmaceuticals, Merck, Julphar, Eli Lilly and Company, Bristol-Myers Squibb Company, Pfizer, AbbVie.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Hypertriglyceridemia Therapeutic Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Hypertriglyceridemia Therapeutic Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Hypertriglyceridemia Therapeutic Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Hypertriglyceridemia Therapeutic Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Hypertriglyceridemia Therapeutic Market Size & Forecast, 2020-2028
4.5.1 Hypertriglyceridemia Therapeutic Market Size and Y-o-Y Growth
4.5.2 Hypertriglyceridemia Therapeutic Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Statins
5.2.2 Fibrates
5.2.3 Niacin
5.2.4 Omega-3 Fatty Acids
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Online Pharmacy
6.2.2 Retail Pharmacy
6.2.3 Hospital Pharmacy
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Hypertriglyceridemia Therapeutic Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Hypertriglyceridemia Therapeutic Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Statins
9.6.2 Fibrates
9.6.3 Niacin
9.6.4 Omega-3 Fatty Acids
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Online Pharmacy
9.10.2 Retail Pharmacy
9.10.3 Hospital Pharmacy
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Statins
10.6.2 Fibrates
10.6.3 Niacin
10.6.4 Omega-3 Fatty Acids
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Online Pharmacy
10.10.2 Retail Pharmacy
10.10.3 Hospital Pharmacy
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Statins
11.6.2 Fibrates
11.6.3 Niacin
11.6.4 Omega-3 Fatty Acids
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Online Pharmacy
11.10.2 Retail Pharmacy
11.10.3 Hospital Pharmacy
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Statins
12.6.2 Fibrates
12.6.3 Niacin
12.6.4 Omega-3 Fatty Acids
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Online Pharmacy
12.10.2 Retail Pharmacy
12.10.3 Hospital Pharmacy
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Statins
13.6.2 Fibrates
13.6.3 Niacin
13.6.4 Omega-3 Fatty Acids
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Online Pharmacy
13.10.2 Retail Pharmacy
13.10.3 Hospital Pharmacy
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Hypertriglyceridemia Therapeutic Market: Competitive Dashboard
14.2 Global Hypertriglyceridemia Therapeutic Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Sanofi
14.3.2 GlaxoSmithKline
14.3.3 Biocon
14.3.4 Novo Nordisk
14.3.5 Tonghua Dongbao Pharmaceutical
14.3.6 Oramed Pharmaceuticals
14.3.7 Merck
14.3.8 Julphar
14.3.9 Eli Lilly and Company
14.3.10 Bristol-Myers Squibb Company
14.3.11 Pfizer
14.3.12 AbbVie
